miR-331-3p is involved in glucocorticoid resistance reversion by rapamycin through suppression of the MAPK signaling pathway.
Lucafò M, Sicari D, Chicco A, Curci D, Bellazzo A, Di Silvestre A, Pegolo C, Autry R, Cecchin E, De Iudicibus S, Collavin L, Evans W, Decorti G, Stocco G.
Lucafò M, et al. Among authors: decorti g.
Cancer Chemother Pharmacol. 2020 Sep;86(3):361-374. doi: 10.1007/s00280-020-04122-z. Epub 2020 Aug 10.
Cancer Chemother Pharmacol. 2020.
PMID: 32776229
Free PMC article.